RA190 --- Ubiquitin Receptor RPN13/ADRM1 Inhibitor

Overview
Catalog #	bs-60163c-2-mg-solid
Product Name	RA190 --- Ubiquitin Receptor RPN13/ADRM1 Inhibitor
Specifications
Storage Buffer	Powder
Storage Condition	Store in dry, dark place at -20C for 1 year.
Target
Product Information	Molecular Weight: 560.3 Formula: C28 H22 Cl4 N2 O2 CAS Number: 1617495-03-0 InChi Key: IYJSFPQYTFFTKN-KJRZKRENSA-N InChi: InChI=1S/C28H22Cl4N2O2/c29-22-8-6-18(12-24(22)31)10-20-15-34(28(36)26(33)14-17-4-2-1-3-5-17)16-21(27(20)35)11-19-7-9-23(30)25(32)13-19/h1-13,26H,14-16,33H2/b20-10+,21-11+/t26-/m0/s1 Smiles: N[C@@H](CC1C=CC=CC=1)C(=O)N1C/C(=C\C2=CC(Cl)=C(Cl)C=C2)/C(=O)/C(/C1)=C/C1=CC(Cl)=C(Cl)C=C1 Purity: 98.0 Solubility: DMSO up to 50 mM Appearance: Solid Power. Shelf Life: 1.0 years
Description	RA190 is a novel potent and selective inhibitor of proteasome Ubiquitin receptor RPN13/ADRM1. It covalently binds to the cysteine 88 of ubiquitin receptor RPN13 in the 19S regulatory particle and inhibits proteasome function, triggering rapid accumulation of polyubiquitinated proteins. Multiple myeloma (MM) lines, even those resistant to bortezomib, were sensitive to RA190 via endoplasmic reticulum stress-related apoptosis. RA190 stabilized targets of human papillomavirus (HPV) E6 oncoprotein, and preferentially killed HPV-transformed cells. After oral or intraperitoneal dosing in mice, RA190 distributed to plasma and major organs except the brain, and inhibited proteasome function in skin and muscle. RA190 administration profoundly reduced growth of MM and ovarian cancer xenografts, and oral RA190 treatment retarded HPV16(+) syngeneic mouse tumor growth, without affecting spontaneous HPV-specific CD8(+) T cell responses, suggesting its therapeutic potential.